Modeling AIDS survival after initiation of antiretroviral treatment by weibull models with changepoints

Journal of the International AIDS Society

Volumn 12, Issue 1, 2009, Pages

  Yiannoutsos, Constantin T ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY; ARTICLE; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTERMEDIATE RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MATHEMATICAL MODEL; MORTALITY RATE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; WEIBULL MODEL;

EID: 74349128686     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-12-9     Document Type: Article

References (22)

1. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg DR, Balestre E, Sterne JA, May M, Egger M: Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006, 367:817-824.
2. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, De Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JAC, the ART Cohort Collaboration: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002, 360:119-129.
3. Stringer JS, Zulu I, Levy J, Stringer EM, Mwango A, Chi BH, Mtonga V, Reid S, Cantrell RA, Bulterys M, Saag MS, Marlink RG, Mwinga A, Ellerbrock TV, Sinkala M: Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006, 296:782-793.
4. Royston P, Parmar MKB: Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002, 21:2175-2197.
5. Noura AA, Read KLQ: Proportional hazards changepoint models in survival analysis. Appl Statist 1990, 39:241-253.
6. Jiwani LJ: Parametric changepoint survival model with application to coronary artery bypass graft surgery data. Master's thesis 2007 [http://www.stat.sfu.ca/people/alumni/Theses/Jiwani-2005.pdf]. Simon Fraser University
7. McCullagh P, Nelder JA: Generalized Linear Models 2nd edition. London: Chapman and Hall; 1991.
8. Hall CB, Lipton RB, Sliwinski M, Stewart WF: A changepoint model for estimating the onset of cognitive decline in pre-clinical Alzheimer's disease. Stat Med 2000, 19:1555-1566.
9. Volinsky CT, Raftery AE: Bayesian Information Criterion for censored survival models. Biometrics 2000, 56:256-262.
10. Home-Based AIDS Care Project, NCT00119093 [http://clini caltrials.gov/ct2/show/NCT00119093?spons=%22Ministry+of+Health%2C+Uganda%22&sp ons_ex=Y&rank=8]
11. Rosen S, Fox MP, Gill CJ: Patient Retention in Antiretroviral Therapy Programs in Sub-Saharan Africa: A Systematic Review. PLoS Medicine 2007, 4:e298.
12. Hjort NL: On inference in parametric survival data models. Int Stat Rev 1992, 60:355-387.
13. Murdoch DM, Venter WD, Feldman C, Van Rie A: Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008, 22:601-610.
14. Seddon J, Mangeya N, Miller RF, Corbett EL, Ferrand RA: Recurrence of cryptococcal meningitis in HIV-infected patients following immune reconstitution. Int J STD AIDS 2009, 20:274-275.
15. Celentano DD, Beyer C, Eds: Public health aspects of HIV/AIDS in low and middle income countries New York: Springer; 2008.
16. Lawn SD, Myer L, Bekker LG, Wood R: Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007, 21:335-341.
17. Jarvis JN, Lawn SD, Vogt M, Bangani N, Wood R, Harrison TS: Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009, 48:856-862.
18. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, Yiannoutsos CT, Musick B, Einterz R, Fife KH, Tierney WM: Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 2006, 20:41-48.
19. Donnelly CA, Bartley LM, Ghani A, Le Fevre AM, Kwong GP, Cowling BJ, Van Sighem AI, De Wolf F, Rode RA, Anderson RM: Gender difference in HIV-1 RNA viral loads. HIV Medicine 2005, 6:170-178.
20. Yiannoutsos CT, An MW, Frangakis CE, Musick BS, Braitstein P, Wools-Kaloustian K, Ochieng D, Martin JN, Bacon MC, Ochieng V, Kimaiyo S: Sampling-based approaches to improve estimation of mortality among patient dropouts: Experience from a large PEPFAR-funded program in western Kenya. PLoS ONE 2008, 3:e3843.
21. Royston P: Flexible parametric alternatives to the Cox model, and more. Stata Journal 2001, 1:1-28 [http://www.stata-journal.com/sjpdf.html?articlenum=st0001].
22. Royston P: Flexible parametric alternatives to the Cox model: update. Stata Journal 2004, 4:98-101 [http://www.stata-journal.com/article.html?article=st0001_2].